Triple negative breast cancers can adopt reversible state that is resistant to chemotherapy
(University of Texas M. D. Anderson Cancer Center) Researchers at The University of Texas MD Anderson Cancer Center have discovered that triple negative breast cancer (TNBC) cells can develop resistance to frontline, or neoadjuvant, chemotherapy not by acquiring permanent adaptations, but rather transiently turning on molecular pathways that protect the cells. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 17, 2019 Category: Biology Source Type: news

Does Neoadjuvant pCR in Melanoma Predict Better Outcomes? Does Neoadjuvant pCR in Melanoma Predict Better Outcomes?
Jeffrey Weber discusses recent trials investigating neoadjuvant combination immunotherapy in patients with melanoma.Medscape Oncology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - April 16, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology Commentary Source Type: news

Implication of Residual TILs in TNBC After Neoadjuvant Chemo Implication of Residual TILs in TNBC After Neoadjuvant Chemo
Do residual disease tumor-infiltrating lymphocyte levels help predict survival after neoadjuvant chemotherapy for TNBC?Annals of Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Neoadjuvant Chemotherapy Key to Survival in Pancreatic Cancer
Three factors independently linked to prolonged survival in BR/LA pancreatic ductal adenocarcinoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 4, 2019 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Surgery, Journal, Source Type: news

Neoadjuvant Chemotherapy Key to Survival in Pancreatic Cancer
THURSDAY, April 4, 2019 -- Three factors can predict survival in patients with borderline resectable (BR) or locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC), according to a study published online April 2 in the Annals of Surgery. Mark... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 4, 2019 Category: Pharmaceuticals Source Type: news

Adding an Oncolytic Virus to Neoadjuvant Chemo for Triple-Negative Breast Cancer
A small early-phase trial tested the addition of the oncolytic virus T-VEC to neoadjuvant chemotherapy in patients with triple-negative breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 1, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

44-Gene Assay Predicts Response, Survival in Esophageal Cancer (CME/CE)
(MedPage Today) -- DNA-damaging immune response in tumors correlates with neoadjuvant therapy efficacy, will aid personalized treatment (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - March 15, 2019 Category: Gastroenterology Source Type: news

Study: Less-Invasive Mesothelioma Surgery Yields Better Results
A team of researchers at the Hyogo College of Medicine in Nishinomiya, Japan, studied the outcomes for pleural mesothelioma patients who received surgery at their facility between 2004 and 2016. The results: More aggressive surgery did not help mesothelioma patients live longer. “We showed that introducing less-invasive surgical techniques could decrease surgical risks without compromising survival,” the researchers wrote in their study, published in January in Seminars in Thoracic and Cardiovascular Surgery. “Surgery that is less invasive than conventional extrapleural pneumonectomy could achieve lower ...
Source: Asbestos and Mesothelioma News - March 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

New Developments in Neoadjuvant Therapy for Lung Cancer
In this article, we review the new developments in neoadjuvant therapy for lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 13, 2019 Category: Cancer & Oncology Authors: Paul A. Bunn, Jr, MD, Erin Schenk, MD, PhD, Jose Pacheco, MD, Anastasios Dimou, MD Source Type: news

Assay Predicts Response, Survival in Esophageal Cancer
(MedPage Today) -- Tumor positivity to DNA-damaging neoadjuvant therapy could hone patient treatment (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - March 12, 2019 Category: Gastroenterology Source Type: news

Mesothelioma Treatment Combines Proton and Photodynamic Therapy
Intraoperative photodynamic therapy combined with novel proton radiation improved survival time significantly for recent patients with advanced-stage pleural mesothelioma. The study — the first to measure the impact of this combination — involved 10 consecutive patients treated at the University of Pennsylvania’s Abramson Cancer Center. The treatment regimen resulted in a 90 percent, two-year disease control rate and an impressive 30.3-month median overall survival from the time of diagnosis. All 10 patients were diagnosed before treatment began with stage 3 or stage 4 disease, which typically results in ...
Source: Asbestos and Mesothelioma News - March 12, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Neoadjuvant Palbociclib Plus Letrozole in Early Breast Cancer Neoadjuvant Palbociclib Plus Letrozole in Early Breast Cancer
Lidia Schapira provides her perspective on a recent study of palbociclib plus letrozole as neoadjuvant therapy for postmenopausal women with ER-positive breast cancer.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 7, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology Viewpoint Source Type: news

Early Response to PD-1 Blockade Predicts Melanoma Outcomes Early Response to PD-1 Blockade Predicts Melanoma Outcomes
The response to a single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in patients with stage III/IV resectable melanoma, researchers report.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 5, 2019 Category: Allergy & Immunology Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Chemotherapy in Advanced Ovarian Cancer Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
Which patients with epithelial ovarian cancer should be considered for neoadjuvant chemotherapy followed by interval debulking surgery?Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Neoadjuvant Anti-PD-1 Predicts Melanoma Outcomes
(MedPage Today) -- One-dose immune response tied to 63% DFS and 93% OS at 2 years (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - February 27, 2019 Category: Dermatology Source Type: news

SABR plus surgery is effective for treating lung cancer
Combining neoadjuvant stereotactic ablative radiotherapy (SABR) with surgery...Read more on AuntMinnie.comRelated Reading: Lung cancer imaging on the upswing in China AI uses features outside nodules to predict malignancy Global lung screening project shows early promise ASTRO: SABR is effective for oligometastatic cancers Australia tries new rad therapy approach for secondary lung cancers (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - February 22, 2019 Category: Radiology Source Type: news

Neoadjuvant PD - 1 Blockade Seems Effective in Glioblastoma
Neoadjuvant pembrolizumab with adjuvant therapy after surgery linked to extended overall survival (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - February 13, 2019 Category: Cancer & Oncology Tags: Neurology, Oncology, Pathology, Pharmacy, Journal, Source Type: news

Neoadjuvant PD-1 Blockade Seems Effective in Glioblastoma
WEDNESDAY, Feb. 13, 2019 -- Neoadjuvant administration of programmed cell death protein 1 (PD-1) blockade seems to enhance local and systemic antitumor immune response in glioblastoma, according to a study published online Feb. 11 in Nature... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 13, 2019 Category: Pharmaceuticals Source Type: news

Neoadjuvant Immunotherapy Yields OS Benefit in Glioblastoma
(MedPage Today) -- Small study finds " timing matters " for anti-PD-1 immunotherapy (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 13, 2019 Category: Hematology Source Type: news

Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced completing the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) for Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) with residual disease after neoadjuvant (before surgery) treatment. (Source: Roche Media News)
Source: Roche Media News - February 5, 2019 Category: Pharmaceuticals Source Type: news

Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced completing the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) for Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) with residual disease after neoadjuvant (before surgery) treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - February 5, 2019 Category: Pharmaceuticals Source Type: news

Pfizer's Trastuzumab Biosimilar Noninferior in Two Breast Ca Trials
(MedPage Today) -- Results similar to branded drug in metastatic, neoadjuvant breast cancer studies (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - February 4, 2019 Category: OBGYN Source Type: news

Neoadjuvant Chemo Ups Survival in Pancreatic Cancer Neoadjuvant Chemo Ups Survival in Pancreatic Cancer
Neoadjuvant chemotherapy significantly improved overall survival in a cohort of Japanese patients and could be a new treatment option, but the regimen is not currently available in the US.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 22, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Smoking Associated With Worse Bladder Cancer Outcomes
FRIDAY, Jan. 11, 2019 -- Cigarette smoking is linked to a poor response to cisplatin-based neoadjuvant chemotherapy (NAC) among patients with muscle-invasive bladder cancer (MIBC) who undergo radical cystectomy (RC), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 11, 2019 Category: Pharmaceuticals Source Type: news

Watch and Wait in Rectal Cancer: Worse Survival for Some Watch and Wait in Rectal Cancer: Worse Survival for Some
A watch-and-wait strategy was associated with improved rectal preservation but poorer survival in patients who achieved a complete response following neoadjuvant therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Tumors backfire on chemotherapy
Some patients with breast cancer receive chemotherapy before the tumor is removed with surgery. This approach, called 'neoadjuvant' therapy, helps to reduce the size of the tumor to facilitate breast-conserving surgery, and can even eradicate the tumor, leaving few or no cancerous cells for the surgeon to remove. In those cases, the patients are very likely to remain cancer-free for life after surgery. (Source: World Pharma News)
Source: World Pharma News - January 2, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Delays to Neoadjuvant Chemotherapy Have Risks in Bladder Cancer
Several factors, including race, insurance, and type of facility, were associated with delays in neoadjuvant chemotherapy treatment for bladder cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Can Anthracyclines be Excluded From Neoadjuvant HER2+ Breast Cancer Tx?
A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 12, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Treatment Response Foretells Events in Breast Cancer Treatment Response Foretells Events in Breast Cancer
A pathological complete response to neoadjuvant therapy is a harbinger of an excellent prognosis for most tumor types in breast cancer.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 6, 2018 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news

SABCS: T - DM1 Cuts Recurrent Invasive HER2 + Breast CA Risk
Risk reduced with trastuzumab emtansine in those with residual invasive dz at sx after neoadjuvant chemo (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 5, 2018 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, Conference News, Source Type: news

Can Anthracyclines be Excluded From Neoadjuvant HER2+ Breast Cancer Tx?
A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 5, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Roche ’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced that the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by 50% (HR=0.50, 95% CI 0.39-0.64, p (Source: Roche Media News)
Source: Roche Media News - December 5, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Kadcyla cut the risk of disease recurring by half compared to Herceptin in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced that the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival; iDFS) by 50% (HR=0.50, 95% CI 0.39-0.64, p (Source: Roche Investor Update)
Source: Roche Investor Update - December 5, 2018 Category: Pharmaceuticals Source Type: news

SABCS: T-DM1 Cuts Recurrent Invasive HER2 & #43; Breast CA Risk
WEDNESDAY, Dec. 5, 2018 -- For patients with residual invasive disease after neoadjuvant chemotherapy including a taxane and trastuzumab, substituting trastuzumab emtansine (T-DM1) for adjuvant trastuzumab is associated with a reduced risk for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 5, 2018 Category: Pharmaceuticals Source Type: news

Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint
(American Association for Cancer Research) Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab reduced the risk of developing an invasive recurrence of HER2-positive early-stage breast cancer by 50 percent, according to data from the phase III clinical trial KATHERINE presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2018 Category: Cancer & Oncology Source Type: news

Adjuvant chemo might not add benefit in breast cancer patients who have excellent response to neoadjuvant chemo
(American Association for Cancer Research) Pathological complete response (pCR) after neoadjuvant (presurgery) chemotherapy was associated with significantly lower recurrence risk and higher overall survival in breast cancer patients, and pCR after neoadjuvant chemotherapy had similar association with improved outcomes among those who received additional chemotherapy following surgery (adjuvant chemotherapy) versus those who did not, according to meta-analyses of data from 52 clinical trials, presented at the 2018 San Antonio Breast Cancer Symposium. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 5, 2018 Category: Cancer & Oncology Source Type: news

What's Hot at SABCS 2018 What's Hot at SABCS 2018
At the world ’ s largest breast cancer meeting, studies on treatment duration, optimal sequencing, and novel neoadjuvant strategies are all on the agenda.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 27, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Chemotherapy or Upfront Surgery in Advanced Ovarian Cancer?
A pooled analysis of two randomized trials found that neoadjuvant chemotherapy and upfront debulking surgery yield similar outcomes in patients with advanced tubo-ovarian cancer, except in some settings. (Source: CancerNetwork)
Source: CancerNetwork - November 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Groundbreaking Results With Pembrolizumab Plus Surgery in Bladder Cancer
The PURE-01 study showed that neoadjuvant pembrolizumab before surgery could downstage disease in muscle-invasive bladder cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - November 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

What Is the Role of EGFR TKIs in Stage III NSCLC?
Previous research showed that gefitinib can improve DFS in certain NSCLC patients, raising the possibility that EGFR-targeted TKIs could be beneficial in the neoadjuvant setting. (Source: CancerNetwork)
Source: CancerNetwork - November 8, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Is Controversy Over NCRT Plus Surgery Warranted in Esophageal Squamous Cell Carcinoma?
A new study adds to evidence examining whether neoadjuvant chemoradiotherapy plus surgery improves survival vs surgery alone in locally advanced ESCC. (Source: CancerNetwork)
Source: CancerNetwork - October 31, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

Roche ’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual di sease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant (before surgery) treatment. (Source: Roche Media News)
Source: Roche Media News - October 15, 2018 Category: Pharmaceuticals Source Type: news

Roche ’s Kadcyla reduced the risk of disease recurring in people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced the phase III KATHERINE study met its primary endpoint, showing Kadcyla ® (trastuzumab emtansine) as a single agent significantly reduced the risk of disease recurrence or death (invasive disease-free survival, iDFS) compared to Herceptin® (trastuzumab) as an adjuvant (after surgery) treatment in people with HER2-positive early breast cancer (eBC) who have residual di sease (pathological invasive residual disease in the breast and/or axillary nodes) present following neoadjuvant (before surgery) treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - October 15, 2018 Category: Pharmaceuticals Source Type: news

Dual Neoadjuvant Checkpoint Blockade Feasible in Melanoma
(MedPage Today) -- Good survival outcomes, but high rates of toxicities, with ipilimumab-nivolumab combo (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - October 12, 2018 Category: Dermatology Source Type: news

Neoadjuvant combination checkpoint blockade trial yields high response rates for patients with high-risk stage three melanoma
(University of Texas M. D. Anderson Cancer Center) Combination checkpoint blockade before surgery (neoadjuvant therapy) produced a high response rate among patients with high-risk stage three melanoma, with nearly half having no sign of disease at surgery, but a high incidence of side effects caused the trial to be closed early. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 8, 2018 Category: International Medicine & Public Health Source Type: news

Do Dose-Dense Neoadjuvant Chemo Regimens Improve Responses in Bladder Cancer?
A dose-dense neoadjuvant chemotherapy regimen yielded higher response rates compared with a standard regimen in a cohort of bladder cancer patients. (Source: CancerNetwork)
Source: CancerNetwork - September 19, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Timing of DWI-MRI predicts breast cancer response
Diffusion-weighted MR images acquired 12 weeks after the start of neoadjuvant...Read more on AuntMinnie.comRelated Reading: Breast cancer follow-up imaging varies widely Breast MRI underutilized in high-risk women Multiparametric MRI shines for suspected breast cancer Is screening breast MRI being used in the wrong women? Breast MRI technique helps cancer detection without contrast (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 11, 2018 Category: Radiology Source Type: news

Which Is Best Neoadjuvant Chemo in Bladder Cancer? Which Is Best Neoadjuvant Chemo in Bladder Cancer?
A nonstandard neoadjuvant chemotherapy was associated with higher complete response rates and more downstaging in patients with muscle-invasive bladder cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 10, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Mayo Clinic physicians receive Stand up to Cancer Catalyst Award for melanoma research
This study, ?Neoactivate?, will test two novel approaches to the treatment of patients with high-risk, stage 3 melanoma guided by specific mutations within [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - September 6, 2018 Category: Hospital Management Source Type: news

' Compelling' Regimen for Resectable Advanced-Stage Melanoma'Compelling' Regimen for Resectable Advanced-Stage Melanoma
Dr Weber reviews a new trial comparing neoadjuvant and adjuvant dual MEK/BRAF inhibition to standard of care in advanced resectable melanoma.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - August 16, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news